跳至主要内容
临床试验/NCT01650064
NCT01650064已完成不适用

Latin America Hip Fracture Mortality Study

AO Clinical Investigation and Publishing Documentation16 个研究点 分布在 8 个国家目标入组 168 人开始时间: 2013年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
168
试验地点
16
主要终点
Death

研究概览

简要总结

The purpose of this study is to estimate the survival proportion one year after surgery for intertrochanteric fracture in older adults in Latin America.

详细描述

This is a multi-center, prospective, observational clinical study to evaluate mortality in patients with surgically-treated hip fracture in Latin America, and investigate associated prognostic factors. Patients will be followed for 12 months.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
60 Years 至 110 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults 60 years and older
  • Diagnosis of an isolated intertrochanteric fracture (AO 31-A) confirmed by radiographic evaluation
  • Primary surgical fracture treatment within 10 days after trauma
  • No prior treatment for the fracture
  • Ability to understand the content of the patient information / informed consent form
  • Willingness and ability to participate in the clinical investigation according to the CIP
  • Signed and dated IRB/EC-approved written informed consent

排除标准

  • Polytrauma (ie, multiple injuries, whereof one or the combination of several injuries is life threatening)
  • Pathologic fracture due to a disease other than osteoporosis (eg, tumor, metastasis)
  • Active malignancy
  • Class 5 and 6 of the American Society of Anesthesiologists (ASA) physical status classification (Appendix 2)
  • Neurological and/or psychiatric disorders that would preclude reliable assessment (eg, Parkinson's disease, multiple sclerosis, severe depression)
  • Recent history of substance abuse (ie, recreational drugs, alcohol) that would preclude reliable assessment
  • Participation in any other medical device or medicinal product study within the previous month that could influence the results of the present study
  • Noncompletion of patient baseline questionnaires
  • Prior implant on the fractured hip

结局指标

主要结局

Death

时间窗: after 1 year

次要结局

  • EQ-5D(Screening/Preoperative, 30±7 days, 60±14 days, 90±21 days, 180±121 days, and 365 (up to 425) days)
  • Wound healing(30±7 days, 60±14 days, and 90± 21 days)
  • Parker Mobility Score(Screening/Preoperative, 30±7 days, 60±14 days, 90± 21 days, 365 (up to 425) days)
  • Anticipated surgical treatment-related adverse events(Postoperative (2 to 5 days), 30±7 days, 60±14 days, 90±21 days, 180±121 days, and 365 (up to 425) days)
  • Harris Hip Score(Screening/Preoperative and 90 ± 21 days)
  • Fracture healing(60±14 days and 90± 21 days)

研究者

发起方
AO Clinical Investigation and Publishing Documentation
申办方类型
Other
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验

Latin America Hip Fracture Mortality Study | 临床试验